Physician profile
Wei Wang
NPI 1861482853
$8,058.94
in general payments reported to CMS, 2019-2025
37 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $1,928 · 2021: $374 · 2022: $171 · 2023: $912 · 2024: $1,432 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,342 · Education: $30.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,342.18 |
| Education | $30.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $1,298.76 | 2019-2023 | Tukysa |
| Pfizer INC. | $954.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $804.13 | 2019-2025 | Enhertu, Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $647.41 | 2019-2025 | |
| Array Biopharma INC | $507.49 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $505.68 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $380.95 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Janssen Biotech, INC. | $293.77 | 2019-2025 | Erleada, Akeega, Balversa |
| Abbvie INC. | $285.72 | 2024-2025 | |
| Daiichi Sankyo INC. | $242.88 | 2024-2025 | Enhertu, Datroway |
| Exelixis INC. | $187.30 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $184.16 | 2020-2023 | Epkinly, Imbruvica |
| Coherus Oncology, INC. | $182.25 | 2024-2025 | Loqtorzi |
| Genentech USA, INC. | $172.79 | 2019-2025 | Tecentriq, Rozlytrek, Polivy |
| Eisai INC. | $155.46 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $129.97 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Amarin Pharma, INC. | $119.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.79 | 2019-2024 | Alunbrig |
| Lilly USA, LLC | $100.60 | 2020-2024 | Verzenio, Retevmo, Jaypirca |
| Gilead Sciences, INC. | $97.72 | 2021-2025 | Trodelvy |
| Stemline Therapeutics INC. | $92.87 | 2024-2025 | Orserdu |
| Medtronic Vascular, INC. | $86.04 | 2019 | |
| Sobi, INC | $73.08 | 2025 | |
| Celgene Corporation | $72.55 | 2019-2025 | Opdivo |
| Genzyme Corporation | $59.55 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $44.87 | 2019-2025 | Gavreto, Tavalisse, Rezlidhia |
| Incyte Corporation | $42.04 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $39.93 | 2025 | Pyrukynd |
| Genmab U.S., INC. | $33.15 | 2025 | Epkinly |
| Iovance Biotherapeutics, INC. | $31.80 | 2025 | Amtagvi |
| Ipsen Biopharmaceuticals, INC | $30.08 | 2024 | Onivyde, Somatuline Depot |
| Accord Healthcare, INC. | $30.02 | 2025 | |
| Legend Biotech USA INC. | $28.10 | 2025 | Carvykti |
| Mylan Institutional INC. | $22.24 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.08 | 2024 | Libtayo |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.